Compare Charles River Laboratories Intl. Inc (CRL) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Liberty Global Ltd Class C — how do they compare? Charles River Laboratories Intl. Inc trades at $303.14 (market cap $14.23B), while Liberty Global Ltd Class C trades at $8.41 (market cap $3.06B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 4.7× Liberty Global Ltd Class C's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Liberty Global Ltd Class C for 21 Days on average.
| CRL | LBTYK | |
|---|---|---|
Market Cap | $14.23B | $3.06B |
Volume | 1,176,885 | 2,508,956 |
Sector | Health | Media |
52-Week High | $310.77 | $12.67 |
52-Week Low | $149.93 | $8.75 |
Typical Hold Time | 33 Days | 21 Days |
Enterprise Value | $17.06B | $9.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
LBTYK trades at $8.65, down 3.03% today and near 52-week lows. The stock shows bearish technical signals with negative earnings trends, including a Q3 2026 net loss of -$3.0B. However, strong analyst support (69% buy ratings) and a $12.67 price target suggest potential upside. Recent developments include the Ziggo Group spin-off preparation and AI partnership with Sierra.
The outlook remains cautious due to persistent losses and bearish technicals, but strategic moves like Ziggo's 2027 listing and solid cash flow ($602M net in 2026) offer recovery potential. Key risks include execution challenges and competitive pressures, while institutional sentiment provides a floor for valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
